Cancer immunotherapy is revolutionizing oncology. However, dose-limiting toxicities and
low patient response rates remain major challenges in the clinic. Cancer nanomedicine in …

Tumor cells do not exist in isolation in vivo, and carcinogenesis depends on the surrounding
tumor microenvironment (TME), composed of a myriad of cell types and biophysical and …

Cancer immunotherapies that train or stimulate the inherent immunological systems to
recognize, attack, and eradicate tumor cells with minimal damage to healthy cells have …

Although notable progress has been made on novel cancer treatments, the overall survival
rate and therapeutic effects are still unsatisfactory for cancer patients …

Cancer immunotherapy is a promising antitumor approach, whereas nontherapeutic side
effects, tumor microenvironment (TME) intricacy, and low tumor immunogenicity limit its …

Cancer immunotherapy evolved as a new treatment modality to eradicate tumor cells and
has gained in popularity after its successful clinical transition. By activating antigen …

Virus-like particles (VLPs) derived from viral nucleocapsids are an important class of
nanoparticles. The structure, uniformity, stability, and function of these VLPs have attracted …

Multivalent presentation of ligands often enhances receptor activation and downstream
signalling. DNA origami offers a precise nanoscale spacing of ligands, a potentially useful …

The first successful use of nanoparticles (NPs) for vaccination was reported almost 40 years
ago with a virus-like particle-based vaccine against Hepatitis B. Since then, the term NP has …

Cancer immunotherapy holds great potential to battle cancer by exerting a durable immunity
effect. However, this process might be limited by various constraints existing in the tumor …